<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246229</url>
  </required_header>
  <id_info>
    <org_study_id>202001</org_study_id>
    <nct_id>NCT04246229</nct_id>
  </id_info>
  <brief_title>Transcutaneous Bilirubinometry and Phototherapy</brief_title>
  <acronym>TRABIN</acronym>
  <official_title>Transcutaneous Bilirubinometry in Neonatal Hyperbilirubinemia During and After Phototherapy: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Princess Amalia Children's Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Princess Amalia Children's Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized Controlled trial comparing the use of transcutaneous bilirubinometry to serum
      bilirubin measurements (via blooddraws = standard care) in neonates born after a gestational
      age &gt; 32 weeks and &lt; 15 days of age treated with Phototherapy for neonatal hyperbilrubinemia.
      Main outcome measurement is the number of blooddraws for measurement of bilirubin. Secondary
      outcome measurements are duration of phototherapy and hospitalisation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized Controlled trial comparing the use of transcutaneous bilirubinometry to serum
      bilirubin measurements (via blooddraws = standard care) in neonates born after a gestational
      age &gt; 32 weeks and &lt; 15 days of age treated with Phototherapy for neonatal hyperbilrubinemia.
      Main outcome measurement is the number of blooddraws for measurement of bilirubin. Secondary
      outcome measurements are duration of phototherapy and hospitalisation.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>blood draws</measure>
    <time_frame>during hospitalisation with a maximum of 14 days</time_frame>
    <description>number of blood draws from the start of phototherapy for measurement of serum bilirubin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>phototherapy duration</measure>
    <time_frame>during hospitalisation with a maximum of 14 days</time_frame>
    <description>duration of phototherapy in hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hospitalisation</measure>
    <time_frame>3 months</time_frame>
    <description>duration of hospitalisation in days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Neonatal Hyperbilirubinemia</condition>
  <arm_group>
    <arm_group_label>transcutaneous bilirubinometry</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>in this arm the bilirubin level to monitor the effect of phototherapy will be measured through transcutaneous mbiirubinometry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>serum bilirubin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this arm the bilirubin level to monitor the effect of phototherapy wil be measured through measurements of serum bilirubin obtained through blood draws</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Transcutaneous bilirubinometry</intervention_name>
    <description>use of transcutaneous bilirubinometry a non-invasieve measurement of skin bilirubin levels</description>
    <arm_group_label>transcutaneous bilirubinometry</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum bilirubin</intervention_name>
    <description>use of blood draws to measure serum bilirubin level</description>
    <arm_group_label>serum bilirubin</arm_group_label>
    <other_name>blood draw</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Neonates with indication for phototherapy for treatment of hyperbilirubinemia

        Exclusion Criteria:

          -  skinlesions located on the sternum interfering with transcutaneous measurement

          -  exchange transfusion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>2 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jolita Bekhof, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>1971</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jolita Bekhof, MD, PhD</last_name>
    <phone>+31384245050</phone>
    <email>j.bekhof@isala.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <state>Overijssel</state>
        <zip>8000 GK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 26, 2020</study_first_submitted>
  <study_first_submitted_qc>January 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Princess Amalia Children's Clinic</investigator_affiliation>
    <investigator_full_name>Jolita Bekhof</investigator_full_name>
    <investigator_title>MD PhD Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>transcutaneous bilirubinometry</keyword>
  <keyword>phototherapy</keyword>
  <keyword>neonatal icterus</keyword>
  <keyword>neonatal jaundice</keyword>
  <keyword>newborn</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperbilirubinemia, Neonatal</mesh_term>
    <mesh_term>Hyperbilirubinemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bilirubin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After publishing the results the individual participant data will be anonimously available upon request</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>after publication in a peer reviewed journal during 3 years</ipd_time_frame>
    <ipd_access_criteria>relevant research question</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

